Beurs gesloten -
OTC Markets
|
Variatie 5 dagen
|
Verschil t.o.v. 1 jan (%)
|
- USD
|
-.--%
|
|
-.--%
|
-.--%
|
Fiscaal tijdperk: december |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Marktkapitalisatie
1 |
19.793
|
21.477
|
9.765
|
6.144
|
6.866
|
9.497
|
-
|
-
|
Bedrijfswaarde
1 |
18.101
|
22.196
|
9.765
|
6.144
|
6.866
|
9.497
|
9.497
|
9.497
|
K/w-verhouding
|
-20,7
x
|
-21
x
|
-9,82
x
|
-8,83
x
|
12,6
x
|
15,9
x
|
13,2
x
|
11,5
x
|
Dividendrendement
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Marktkapitalisatie/omzet
|
218
x
|
36,6
x
|
5,8
x
|
1,91
x
|
1,27
x
|
1,62
x
|
1,47
x
|
1,28
x
|
Bedrijfswaarde/omzet
|
218
x
|
36,6
x
|
5,8
x
|
1,91
x
|
1,27
x
|
1,62
x
|
1,47
x
|
1,28
x
|
Bedrijfswaarde/EBITDA
|
-25,7
x
|
-25
x
|
-23,3
x
|
-19,8
x
|
6,72
x
|
8,77
x
|
7,83
x
|
6,73
x
|
Bedrijfswaarde/FCF
|
-14,5
x
|
-17,8
x
|
-9,38
x
|
-
|
12
x
|
25,4
x
|
26,6
x
|
11,1
x
|
FCF Yield
|
-6,89%
|
-5,62%
|
-10,7%
|
-
|
8,36%
|
3,94%
|
3,76%
|
8,98%
|
Price to Book
|
4,53
x
|
6,71
x
|
4,25
x
|
3,75
x
|
-
|
3,36
x
|
2,86
x
|
2,36
x
|
Aantal aandelen (in duizenden)
|
543.495
|
543.495
|
543.495
|
543.495
|
543.495
|
543.495
|
-
|
-
|
Referentieprijs
2 |
36,42
|
39,52
|
17,97
|
11,30
|
12,63
|
17,47
|
17,47
|
17,47
|
Datum van publicatie
|
23-03-20
|
26-03-21
|
16-03-22
|
31-03-23
|
21-03-24
|
-
|
-
|
-
|
Fiscaal tijdperk: december |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Omzet
1 |
90,93
|
587,6
|
1.682
|
3.215
|
5.395
|
5.875
|
6.451
|
7.411
|
EBITDA
1 |
-768,7
|
-857,8
|
-420
|
-310,6
|
1.021
|
1.083
|
1.213
|
1.410
|
Bedrijfsresultaat (EBIT)
1 |
-851,2
|
-993,6
|
-620,2
|
-323,8
|
662
|
751
|
851,2
|
1.075
|
Operationele Marge
|
-936,09%
|
-169,09%
|
-36,86%
|
-10,07%
|
12,27%
|
12,78%
|
13,2%
|
14,51%
|
Resultaat voor belastingen (EBT)
1 |
-874,8
|
-993,5
|
-956,7
|
-693,9
|
569,6
|
662,5
|
804,6
|
953
|
Nettowinst (verlies)
1 |
-875,5
|
-993,5
|
-984,1
|
-695,3
|
546
|
594,4
|
709,7
|
887,2
|
Nettomarge
|
-962,8%
|
-169,09%
|
-58,49%
|
-21,63%
|
10,12%
|
10,12%
|
11%
|
11,97%
|
WPA
2 |
-1,760
|
-1,880
|
-1,830
|
-1,280
|
1,000
|
1,101
|
1,323
|
1,521
|
Free Cash Flow
1 |
-1.364
|
-1.207
|
-1.041
|
-
|
574,2
|
374
|
357
|
853
|
FCF-marge
|
-1.500,51%
|
-205,34%
|
-61,86%
|
-
|
10,64%
|
6,37%
|
5,53%
|
11,51%
|
Kasstroomconversie (ebitda)
|
-
|
-
|
-
|
-
|
56,23%
|
34,54%
|
29,43%
|
60,49%
|
Kasstroomconversie (nettowinst)
|
-
|
-
|
-
|
-
|
105,17%
|
62,92%
|
50,31%
|
96,15%
|
Dividend per aandeel
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Datum van publicatie
|
23-03-20
|
26-03-21
|
16-03-22
|
31-03-23
|
21-03-24
|
-
|
-
|
-
|
Fiscaal tijdperk: december |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Nettoschuldpositie
|
-
|
719
|
-
|
-
|
-
|
-
|
-
|
-
|
Nettokaspositie
|
1.692
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Hefboom (schuld/ebitda)
|
-
|
-0,8386
x
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-1.364
|
-1.207
|
-1.041
|
-
|
574
|
374
|
357
|
853
|
ROE (netto-inkomsten/eigen vermogen)
|
-30,2%
|
-27,6%
|
-35,8%
|
-35,4%
|
28,5%
|
27%
|
28,7%
|
28,3%
|
ROA (netto-inkomsten/totale activa)
|
-
|
-16,1%
|
-
|
-
|
-
|
6,9%
|
6,05%
|
6,4%
|
Totale activa
1 |
-
|
6.169
|
-
|
-
|
-
|
8.614
|
11.730
|
13.862
|
Nettoactief per aandeel
2 |
8,050
|
5,890
|
4,230
|
3,010
|
-
|
5,200
|
6,100
|
7,400
|
Cashflow per aandeel
|
-
|
-1,230
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
289
|
557
|
460
|
585
|
474
|
675
|
602
|
588
|
Capex/omzet
|
317,77%
|
94,79%
|
27,37%
|
18,2%
|
8,78%
|
11,48%
|
9,33%
|
7,93%
|
Datum van publicatie
|
23-03-20
|
26-03-21
|
16-03-22
|
31-03-23
|
21-03-24
|
-
|
-
|
-
|
Gemiddeld advies Accumuleren Laatste slotkoers
17,47
CNY Gemiddelde koersdoel
16,7
CNY Spread / Gemiddelde doel -4,42% Consensus |
Vaira. 1 jan.
|
Kapi.
|
---|
| -2,29% | 89,38 mld. | | -3,95% | 37,92 mld. | | -13,07% | 32,04 mld. | | +63,05% | 26,03 mld. | | -22,14% | 14,14 mld. | | -7,96% | 12,88 mld. | | -9,33% | 11,77 mld. | | -46,33% | 10,85 mld. | | +5,77% | 8,92 mld. |
Biofarmaceutica
|